1-4 of 4
Michael O'Neill, PhD
Close
Sort by
Journal Articles

Cotargeting of PIM, PI3K and Mtor in Mantle Cell Lymphoma (MCL)

Bianca Freysoldt, Andrea Schnaiter, MD, Luca Fischer, Michael O'Neill, PhD, Yvonne Zimmermann, Grit Hutter, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2015) 126 (23): 5120.
https://doi.org/10.1182/blood.V126.23.5120.5120
Published: 2015
Journal Articles

The Dual PIM/PI3-K Inhibitor Ibl-202 Overcomes Microenvironmental Mediated Resistance in Multiple Myeloma and Prevents PIM1 Induced CXCR4 Upregulation

Mairead Reidy, PhD, Marianne VanDijk, PhD, Michael O'Neill, PhD, Michael O'Dwyer, MD FRCPI, FRCPath
Journal: Blood
Blood (2015) 126 (23): 5350.
https://doi.org/10.1182/blood.V126.23.5350.5350
Published: 2015
Journal Articles

Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia

Oliver Giles Best, PhDBSc, Kyle Crassini, MBBS BSc, Michael O'Neill, PhD, Michael E O'Dwyer, MD FRCPI, FRCPath, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA
Journal: Blood
Blood (2014) 124 (21): 4693.
https://doi.org/10.1182/blood.V124.21.4693.4693
Published: 2014
Journal Articles

Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma

Mairead Reidy, PhD, Marianne vanDijk, PhD, Niamh Keane, MB BCh BAO, Michael O'Neill, PhD, Michael E O'Dwyer, MD FRCPI, FRCPath
Journal: Blood
Blood (2014) 124 (21): 5713.
https://doi.org/10.1182/blood.V124.21.5713.5713
Published: 2014